Safety of Concomitant Triptan and INP104 Use From the Phase 3 STOP 301 Study in Migraine Patients

Presented at the AHS 65th Annual Scientific Meeting, June 15-18, 2023, Austin, Texas Authors: Feoktistov A, Vann R, Gutierrez J, Ray S, Shrewsbury S, Aurora S One sentence summary: The safety in migraine patients of concomitant triptan and INP104 (dihydroergotamine mesylate and Precision Olfactory Delivery) use is reported from the Phase 3 STOP 301 study. Background: INP104 […] The post Safety of Concomitant Triptan and INP104 Use From the Phase 3 STOP 301 Study in Migraine Patients appeared first on Impel Pharmaceuticals .